Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib by Hehlgans, Stephanie et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell
Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib
Hehlgans, Stephanie ; Booms, Patrick ; Güllülü, Ömer ; Sader, Robert ; Rödel, Claus ; Balermpas,
Panagiotis ; Rödel, Franz ; Ghanaati, Shahram
Abstract: Vismodegib, an inhibitor of the Hedgehog signaling pathway, is an approved drug for monother-
apy in locally advanced or metastatic basal cell carcinoma (BCC). Data on combined modality treatment
by vismodegib and radiation therapy, however, are rare. In the present study, we examined the radiation
sensitizing effects of vismodegib by analyzing viability, cell cycle distribution, cell death, DNA damage
repair and clonogenic survival in three-dimensional cultures of a BCC and a head and neck squamous
cell carcinoma (HNSCC) cell line. We found that vismodegib decreases expression of the Hedgehog tar-
get genes glioma-associated oncogene homologue (GLI1) and the inhibitor of apoptosis protein (IAP)
Survivin in a cell line- and irradiation-dependent manner, most pronounced in squamous cell carcinoma
(SCC) cells. Furthermore, vismodegib significantly reduced proliferation in both cell lines, while addi-
tional irradiation only slightly further impacted on viability. Analyses of cell cycle distribution and cell
death induction indicated a G1 arrest in BCC and a G2 arrest in HNSCC cells and an increased fraction
of cells in SubG1 phase following combined treatment. Moreover, a significant rise in the number of phos-
phorylated histone-2AX/p53-binding protein 1 (￿H2AX/53BP1) foci in vismodegib- and radiation-treated
cells was associated with a significant radiosensitization of both cell lines. In summary, these findings
indicate that inhibition of the Hedgehog signaling pathway may increase cellular radiation response in
BCC and HNSCC cells.
DOI: https://doi.org/10.3390/ijms19092485
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-184290
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Hehlgans, Stephanie; Booms, Patrick; Güllülü, Ömer; Sader, Robert; Rödel, Claus; Balermpas, Pana-
giotis; Rödel, Franz; Ghanaati, Shahram (2018). Radiation Sensitization of Basal Cell and Head and
Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib. International Journal
of Molecular Sciences, 19(9):2485.
DOI: https://doi.org/10.3390/ijms19092485
 International Journal of 
Molecular Sciences
Article
Radiation Sensitization of Basal Cell and Head and
Neck Squamous Cell Carcinoma by the Hedgehog
Pathway Inhibitor Vismodegib
Stephanie Hehlgans 1,*,†, Patrick Booms 2,†, Ömer Güllülü 1, Robert Sader 2, Claus Rödel 1,
Panagiotis Balermpas 1 ID , Franz Rödel 1,† and Shahram Ghanaati 2,†
1 Department of Radiotherapy and Oncology, Medical Center Goethe-University Frankfurt am Main,
60590 Frankfurt am Main, Germany; Oemer.Guelluelue@kgu.de (Ö.G.); Claus.Roedel@kgu.de (C.R.);
Panagiotis.Balermpas@kgu.de (P.B.); Franz.Roedel@kgu.de (F.R.)
2 Department for Oral, Cranio-Maxillofacial and Facial Plastic Surgery, Frankfurt Orofacial Regenerative
Medicine (FORM), Medical Center Goethe-University Frankfurt am Main,
60590 Frankfurt am Main, Germany; Patrick.Booms@kgu.de (P.B.); Robert.Sader@kgu.de (R.S.);
Shahram.Ghanaati@kgu.de (S.G.)
* Correspondence: Stephanie.Hehlgans@kgu.de; Tel.: +49-69-6301-4838
† These authors contributed equally to this work.
Received: 10 August 2018; Accepted: 21 August 2018; Published: 23 August 2018


Abstract: Vismodegib, an inhibitor of the Hedgehog signaling pathway, is an approved drug for
monotherapy in locally advanced or metastatic basal cell carcinoma (BCC). Data on combined
modality treatment by vismodegib and radiation therapy, however, are rare. In the present study, we
examined the radiation sensitizing effects of vismodegib by analyzing viability, cell cycle distribution,
cell death, DNA damage repair and clonogenic survival in three-dimensional cultures of a BCC and a
head and neck squamous cell carcinoma (HNSCC) cell line. We found that vismodegib decreases
expression of the Hedgehog target genes glioma-associated oncogene homologue (GLI1) and the
inhibitor of apoptosis protein (IAP) Survivin in a cell line- and irradiation-dependent manner, most
pronounced in squamous cell carcinoma (SCC) cells. Furthermore, vismodegib significantly reduced
proliferation in both cell lines, while additional irradiation only slightly further impacted on viability.
Analyses of cell cycle distribution and cell death induction indicated a G1 arrest in BCC and a
G2 arrest in HNSCC cells and an increased fraction of cells in SubG1 phase following combined
treatment. Moreover, a significant rise in the number of phosphorylated histone-2AX/p53-binding
protein 1 (γH2AX/53BP1) foci in vismodegib- and radiation-treated cells was associated with a
significant radiosensitization of both cell lines. In summary, these findings indicate that inhibition of
the Hedgehog signaling pathway may increase cellular radiation response in BCC and HNSCC cells.
Keywords: basal cell carcinoma; head and neck squamous cell carcinoma; hedgehog signaling
pathway; radiotherapy resistance; vismodegib (GDC-0449)
1. Introduction
Non-melanoma skin cancer, or keratinocyte carcinoma, is the most common malignancy among
Caucasians and its incidence continues to rise annually [1]. This entity comprises basal cell carcinoma
(BCC) and squamous cell carcinoma (SCC), together with a host of rare tumors [2,3]. BCC arises
from abnormal growth of the skin’s basal cells, which line the deepest layer of the epidermis, with
ultraviolet light exposure to constitute an essential risk factor in the development of malignancy [4].
The mechanisms of origin of BCCs have been extensively analyzed within the last decades. Briefly, a
reactivation of the hedgehog (Hh) signaling pathway has been involved in tumorigenesis in human
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BCC [5]. In an unaffected individual, the Hh signaling pathway is inhibited by patched homologue 1
(PTCH1) and gets activated upon binding of Hh ligand to its transmembrane receptor smoothened
(SMO). SMO is a G-protein-coupled receptor (GPCR)-like receptor that transfers signals through
various proteins resulting in an increased expression of target genes, such as glioma-associated
oncogene homologue zinc-finger transcription activator (GLI1) [6]. An estimated 80–90% of sporadic
BCC tumors have PTCH1 mutations, whereas 10% harbor SMO mutations. In either scenario, these
alterations lead to unopposed SMO signaling and BCC development [7,8].
Recent data indicate that the inhibitor of apoptosis protein (IAP) Survivin comprises a novel target
of the Hh/GLI signaling pathway [9]. Direct proof of GLI2 transcription factor binding to the Survivin
promoter, promoter activity assays and Survivin downregulation upon Hh/GLI signaling inhibition
by SMO inhibitor cyclopamine, or GLI inhibitor GANT61 identified Survivin as a transcriptional
target of GLI2 in a variety of tumor cells of different origin as well as in a murine tumor model [9].
A hampered Survivin expression following SMO inhibition has further been described for malignant
pleural mesothelioma, an effect rescued by overexpression of GLI1, suggesting an involvement of
GLI1 transcription factor [10]. Importantly, Survivin is frequently overexpressed in malignant cells,
confers chemo- and radiation resistance by multiple pathways including inhibition of Caspase-3 and
-7 activity and p53-mediated apoptosis [11] and has been associated with poor clinical outcome [12].
In 2012, the Hh pathway inhibitor vismodegib (GDC-0449), an oral small molecule inhibitor of
SMO was the first drug to gain U.S. Food and Drug Administration approval for treatment of advanced
BCC, metastasized BCC, relapsed BCC after surgery, or BCC that cannot be treated with surgery or
radiation [13,14]. Vismodegib monotherapy has been shown to contribute to significant response
rates between 30% and 43% (phase 1 study) among patients with advanced BCC [15]. Moreover,
preclinical and clinical data indicate that an aberrant Hh signaling [16,17], mutations in PTCH1 and
SMO and overexpression of components of the Hh pathway all correlate with poor clinical outcome
in gastric [18], esophageal cancer [19] and in head and neck SCC (HNSCC) [20,21]. In line with that,
inhibition of Hh pathway if combined with radiation or radiochemotherapy (RCT), has been shown to
result in improved therapeutic responses and survival, without increased unexpected side effects in a
variety of preclinical models and clinical reports including non-small cell lung cancer [22], esophageal
cancer [19], and HNSCC [16]. Moreover, combining vismodegib and radiotherapy (RT) displays a
beneficial therapeutic effect on BCC [23,24] as shown by our group for locally advanced tumors of the
head and neck region [25]. In the present study, we aimed to confirm a radiation sensitizing effect of
vismodegib in a BCC and an HNSCC cell line.
2. Results
2.1. Impact of Vismodegib Concentration and Treatment Time on Cell Proliferation/Viability
In order to identify suitable vismodegib concentrations and treatment schedules, we treated
BCC-1 and SCC-25 cells with increasing amounts of vismodegib ranging from 5 to 40 µM for 3 to 96 h
and applied a colorimetric cell proliferation assay (MTS) (Figure 1A). Cellular proliferation/viability
was significantly decreased in a concentration dependent manner within 3 h of treatment with 5 to
40 µM vismodegib, while elongated treatment time up to 96 h only slightly further decreased the
cell proliferation/viability in BCC-1 and SCC-25 cells (Figure 1B,C). Notably, we did not reach IC50
values indicating the necessity to further increase the therapeutic effects by combining with additional
treatment options.
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Figure 1. Vismodegib reduces the number of viable BCC-1 and SCC-25 cells. Relative quantification 
of cellular metabolic activity (i.e., number of viable cells) was performed for cells treated with 
vismodegib compared to dimethyl sulfoxide (DMSO) controls using a CellTiter 96® Aqueous One 
Solution Cell Proliferation (MTS) Assay. (A) Time schedule of vismodegib treatment and 
measurement of colorimetric cell proliferation assay. BCC-1 or SCC-25 cells were plated 24 h before 
treatment with vismodegib for 3 to 96 h before analysis. Metabolic activity is expressed as relative 
absorption at 490 nm. This assay was carried out in five independent experiments (each in 
quadruplicate) for BCC-1 (B) and SCC-25 (C) cells. The metabolic activity of controls was set to 1.0 
(i.e., reference value) as indicated. Statistical significance was assessed by t-test; * p < 0.05, ** p < 0.01 
(vismodegib- versus DMSO-treated cells). BCC, basal cell carcinoma; Rel., relative; SCC, squamous 
cell carcinoma; Vism., vismodegib. 
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Manner 
To confirm a vismodegib-mediated inhibition of Hh signaling, we applied quantitative 
real-time PCR and immunoblotting monitoring the expression of Hh target genes GLI1 and Survivin 
at 24 h and 48 h after vismodegib treatment (Figures 2 and S1). GLI1 mRNA expression was 
significantly decreased after 24 h of treatment with 40 µM vismodegib in both cell lines while BCC-1 
cells further revealed slightly but significantly reduced GLI1 mRNA levels after 48 h (Figure 2B). The 
low effects of Hh inhibition in both BCC-1 and SCC-25 cells may be attributed to a weak expression 
of GLI1 protein. Therefore, we compared levels of detection to a HT-29 colorectal cell line, reported 
to express higher amounts of the protein. As depicted in Figure S2, we detected a pronounced GLI1 
band in the HT-29 samples, but a lesser staining in BCC-1 and SCC-25 cells in favor of a weak 
responsiveness to Hh inhibitor in the latter cell lines. Concerning the expression of Survivin (BIRC5), 
we observed a slight reduction after 24 and 48 h of vismodegib treatment in the BCC-1 cell line, 
while survivin expression was not affected in SCC-25 cells on the level of RNA expression (Figure 
Figure 1. Vismodegib reduces the number of viable BCC-1 and SCC-25 cells. Relative quantification of
cellular etabolic activity (i.e., number of viable cells) was performed for cells treated with vismodegib
compared to dimethyl sulfoxide (DMSO) controls using a CellTiter 96® Aqueous One Solution Cell
Prolifer tion (MTS) Assay. (A) Time schedule f vismodegib treatment and measurement of colorimetric
cell p oliferation assay. BCC-1 SCC-25 cells were plated 24 h before treatment with vismodegib for
3 to 96 h before analysis. Metabolic activity is expressed as relative absorption at 490 nm. This assay
was carried out in five independent experiments (each in quadruplicate) for BCC-1 (B) and SCC-25
(C) cells. The metabolic activity of controls was set to 1.0 (i.e., reference value) as indicated. Statistical
significance was assessed by t-test; * p < 0.05, ** p < 0.01 (vismodegib- versus DMSO-treated cells). BCC,
basal cell carcinoma; Rel., relative; SCC, squamous cell carcinoma; Vism., vismodegib.
2.2. Vismodegib Decreases Hh Signaling Target Gene GLI1 and Survivin Expression in a Cell
Line-Dependent Manner
To confirm a vismodegib-mediated inhibition of Hh g aling, we appli d quantitative real-time
PCR nd immunoblotting monit ring the expression of Hh t rget genes GLI1 and Survivin at 24 h and
48 h after vismodegib treatment (Figure 2 and Figure S1). GLI1 mRNA expression as significantly
decreased after 24 h of treatment with 40 µM vismodegib in both cell lines while BCC-1 cells further
revealed slightly but significantly reduced GLI1 mRNA levels after 48 h (Figure 2B). The low effects of
Hh inhibition in both BCC-1 and SCC-25 cells may be attributed to a weak expression of GLI1 protein.
Therefore, we compared levels of detection to a HT-29 colorectal cell line, reported to express higher
amounts of the protein. As depicted in Figure S2, we detected a pronounced GLI1 band in the HT-29
sampl s, ut a lesser staining in BCC-1 and SCC-25 cells in favor of a weak r sponsiv ness to Hh
inhibitor in the latt r c ll li es. Concerning the expression f Survi in (BIRC5), we observed a slight
reduction after 24 and 48 h of vismodegib treatment in the BCC-1 cell line, while survivin expression
was not affected in SCC-25 cells on the level of RNA expression (Figure 2C). According to Western
blotting (Figure 2D) and densitometric analysis (Figure S1A), vismodegib treatment decreased both
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GLI1 protein levels in BCC-1 and SCC-25 cells. Notably, Survivin protein expression was slightly
but significantly reduced on the protein level (Figure S1B) in SCC-25 cells indicating a putative
non-transcriptional regulation following vismodegib treatment.
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2.3. Vismodegib Treatment and Irradiation Modulate Cell Viability, Cell Cycle Distribution and Cell Death 
To analyze vismodegib- and irradiation-dependent viability/proliferation, MTS assays were 
performed according to the schedules depicted in Figure 3A. Following combined 
Figure 2. Vismodegib decreases hedgehog (Hh) target gene glioma-associated oncogene homologue
1 (GLI1) and Survivin expression. (A) Time schedule of vismodegib pplication and RNA/protein
extraction for analysis. BCC-1 or SCC-25 cells were plat d 24 h before treatment with 10 or 40 µM
vismodegib or with DMSO as control for 24 h or 48 h before analysis. (B) mRNA expression for
GLI1 and Survivin (C) relative to DMSO-treated controls. n = 2 (in duplicate); * p < 0.05, ** p < 0.01
(vismodegib- versus DMSO-treated cells, t-test). (D) Representative Western blots from at least two
independent experiments, including detection of p53 expression in the cell lines. β-actin served as
loading control. Rel., relative; Vism., vismodegib.
2.3. Vismodegib Treatment and Irradiation Modulate Cell Viability, Cell Cycle Distribution and Cell Death
To analyze vismodegib- and irradiation-dependent viability/proliferation, MTS assays were
performed according to the schedules depicted in Figure 3A. Following combined vismodegib/radiation
treatment, we only observed a slight impact of irradiation with 4 Gy on both cell lines investigated
(Figure 3B). Since a cell cycle arrest may underlie these findings, we next assayed cell cycle distribution
of vismodegib-treated and irradiated BCC-1 cells and found a decreased number of S phase cells,
corresponding to an increased fraction of cells in the G1 phase after combined treatment (Figure 3C and
Figure S3). In contrast, analysis of SCC-25 cells revealed a G2 phase arrest upon combined-modality
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treatment (Figure 3C) that might be associated with the lack of p53 expression in the cell line as depicted
in Figure 2D. Additionally, we checked the SubG1 cell population to determine cell death induction
upon Hh inhibition and irradiation. Vismodegib treatment significantly enhanced the fraction of cells
in the SubG1 phase in both cell lines, although at a low level. Additional irradiation with 4 Gy further
increased SubG1 cell counts with significant values in BCC-1 cells treated with 40 µM vismodegib
(Figure 3D and Figure S3). Finally, Western blot analyses revealed neither increased Caspase-3 nor Poly
((adenosine diphosphate)ADP-ribose) polymerase (PARP) cleavage upon vismodegib and irradiation
treatment at the investigated time points (Figure 3E).
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  5 of 15 
 
vismodegib/radiation treatment, we only observed a slight impact of irradiation with 4 Gy on both cell 
lines investigated (Figure 3B). Since a cell cycle arrest may underlie these findings, we next assayed cell 
cycle distribution of vismodegib-treated and irradiated BCC-1 cells and found a decreased number of 
S phase cells, corresponding to an increased fraction of cells in the G1 phase after combined treatment 
(Figures 3C and S3). In contrast, analysis of SCC-25 cells revealed a G2 phase arrest upon 
combined-modality treatment (Figure 3C) that might be associated with the lack of p53 expression in 
the cell line as depicted in Figure 2D. Additionally, we checked the SubG1 cell population to determine 
cell death induction upon Hh inhibition and irradiation. Vismodegib treatment significantly enhanced 
the fraction of cells in the SubG1 phase in both cel  lines, although at a low l vel. Add tional irradiat on 
with 4 Gy further increased SubG1 cell counts with significant values in BCC-1 cells treated with 40 
µM vismodegib (Figures 3D and S3). Finally, Western blot analyses revealed neither increased 
Caspase-3 nor Poly ((adenosine diphosphate)ADP-ribose) polymerase (PARP) cleavage upon 
vismodegib and irradiation treatment at the investigated time points (Figure 3E). 
 
Figure 3. Vismodegib and irradiation modulate cell viability, cell cycle distribution and SubG1 cell 
fraction content. BCC-1 and SCC-25 cells were pretreated for 24 h with indicated concentrations of 
vismodegib or DMSO as control before a 4 Gy irradiation (A). At 24 h after irradiation, 
proliferation/viability was measured with a CellTiter 96® Aqueous One Solution Cell Proliferation 
(MTS) Assay (B). Cell cycle distribution (C) and SubG1 cell fraction (D) were analyzed after propidium 
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Figure 3. Vismodegib and irradiation modulate cell viability, cell cycle distribution and SubG1 cell
fraction content. BCC-1 and SCC-25 cells were pretreated for 24 h with indicated concentrations
of vismodegib or DMSO as control before a 4 Gy irradiation (A). At 24 h after irradiation,
proliferation/viability was measured with a CellTiter 96® Aqueous One Solution Cell Proliferation
(MTS) Assay (B). Cell cycle distribu ion (C) and SubG1 cell fraction (D) were analyzed aft r propidium
iodide staining by flow cytometric quantification. Caspase 3 and PARP expression/cleavage was
detected by Western blotting (n = 2) with β-actin as loading control (E). Data given in (B–D) are
shown as means + SD from four independent experiments with quadruplicates (MTS assay, (A))
or duplicates (flow cytometry (B,C)). Differences were considered as statistically significant when
* p < 0.05 or highly significant when ** p < 0.01; vismodegib- versus DMSO-treated cells (t-test).
Significant differences between irradiated and non-irradiated cells are indicated as follows: # p < 0.05,
## p < 0.01 (t-test). Gy, Gray; PARP, poly ((adenosine diphosphate)ADP-ribose) polymerase; Rel.,
relative; Vism., vismodegib.
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2.4. Vismodegib Increases Radiation-Induced DNA Damage of BCC-1 and SCC-25 Cells
Since the Hh/GLI signaling pathway and the target gene Survivin have been described to be
involved in DNA repair mechanisms [26–28], we investigated the impact of vismodegib on DNA
double-strand break (DSB) repair by quantification of γH2AX/p53-binding protein 1 (53BP1) foci
detection (Figure 4A). While vismodegib monotherapy does not increase γH2AX/53BP1 nuclear
foci in non-irradiated BCC-1 or SCC-25 cells, a combination of vismodegib and 4 Gy-irradiation
significantly enhanced the number of persisting (24 h) foci in a concentration-dependent manner
(Figure 4). Notably, basal γH2AX/53BP1 foci levels are much higher in SCC-25 HNSCC as compared
to BCC-1 cells (Figure 4).
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vismodegib-treated cells are shown. Nuclei were counterstained with DAPI. Scale bar, 10 µm. (B) 
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and SCC-25 (right panel) cells. Bars represent means + SD from three independent experiments 
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Figure 4. Vismodegib increases radiation-induced γH2AX/53BP1 nuclear foci. BCC-1 or SCC-25 cells
were treated for 24 h with 10 or 40 µM vismodegib or with DMSO as control followed by irradiation with
4 Gy. (A) Representative images of phosphorylated gamma histone-2AX (γH2AX)/p53-binding protein
1 (53BP1) foci from non-irradiated and 4 Gy-irradiated DMSO control versus 40 µM vismodegib-treated
cells are shown. Nuclei were counterstained with DAPI. Scale bar, 10 µm. (B) Quantification of
persistent γH2AX/53BP1 foci in vismodegib treated and irradiated BCC-1 (left panel) and SCC-25
(right panel) cells. Bars represent means + SD from three ind pende t experiments performed in
duplicate. ** p < 0.01 vismodegib- versus DMSO-treated cells and # p < 0.05, ## p < 0.01 4 Gy versus
non-irradiated cells (t-test). Gy, Gray; Vism., vismodegib.
2.5. Vismodegib Radiosensitizes BCC-1 and SCC-25 Cells
Finally, we evaluated long-term effects of vismodegib treatment in combination with irradiation in
a more physiological cell culture model by applying 3D clonogenic survival assays (Figure 5A) [29,30].
Single vismodegib treatment does not impact on the basal plating efficiency of BCC-1 and SCC-25
cells (Figure 5B). In contrast, the drug significantly radiosensitized BCC-1 and SCC-25 cells in a
concentration-dependent manner (Figure 5C).
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Figure 5. Vismodegib sensitizes basal and squamous cell carcinoma cells to ionizing radiation in a
3D clonogenic assay. BCC-1 and SCC-25 cells were plated as single cells in a three-dimensional (3D)
laminin-rich extracellular matrix and were treated with vismodegib 24 h before irradiation with 0 to
8 Gy, single doses. (A) 7 days aft r plating, representative images of 3D grown colo ies were acquired.
Scale bar, 100 µm. (B) Colonies were counted micro copically from three independent xperiments
performed in triplicate. Basal plating efficiencies of cells treated with 5 to 40 µM vismodegib, are
shown relative to DMSO-treated control cells. (C) Surviving fractions and radiation survival curves
were calculated as described in the Materials and Methods section. Values represent means ± SD
(n = 3). * p < 0.05, ** p < 0.01; vismodegib-treated cells versus DMSO control (t-test). Gy, Gray;
Vism., vismodegib.
Radiation response variables and significances are summarized in Table 1 and Table S1.
The radiation-induced cytotoxicity enhancement factors at 50% cell survival comparing 5, 10 or
40 µM vismodegib versus dimethyl sulfoxide (DMSO) control were 1.51, 1.45, and 1.73 for BCC-1 cells,
and 1.48, 1.79, and 1.81 for SCC-25 cells (Table 1)—indicating clear radiation sensitizing effects.
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Table 1. Radiation response variables of vismodegib-treated BCC-1 and SCC-25 cells.
Cell Line
Treatment
Plating
Efficiency
[%]
α
[Gy−1]
β
[Gy−2]
Radiation Dose
at 50% Cell
Survival [Gy]
Sensitizer
Enhancement
Ratio (versus
DMSO
Control)
Radiation
Dose at 10%
Cell Survival
[Gy]
Sensitizer
Enhancement
Ratio (versus
DMSO
Control)
BCC-1
DMSO 23.29 ± 3.39 0.0428 0.0307 4.10 7.99
5 µM Vism. 25.00 ± 3.67 0.2348 0.0074 2.72 1.51 7.85 1.02
10 µM Vism. 24.29 ± 4.84 0.2044 0.0147 2.82 1.45 7.37 1.08
40 µM Vism. 21.11 ± 1.54 0.2724 0.0084 2.37 1.73 6.96 1.15
SCC-25
DMSO 28.56 ± 2.52 0.0849 0.0290 3.64 7.57
5 µM Vism. 29.44 ± 1.67 0.2479 0.0138 2.46 1.48 6.75 1.12
10 µM Vism. 31.53 ± 5.59 0.3189 0.0104 2.04 1.79 6.03 1.25
40 µM Vism. 22.39 ± 2.43 0.3152 0.0143 2.02 1.81 5.79 1.31
The linear quadratic equation (SF = exp [−α × D − β × D2]) with fitted α and β values of the individual survival
curves was transformed to calculate radiation-induced cytotoxicity enhancement factors at 50% and 10% cell
survival versus DMSO controls. D, radiation dose [Gy]; DMSO, control cells treated with equivalent amounts of
DMSO; SF, surviving fraction; Vism., vismodegib-treated cells using indicated concentrations.
3. Discussion
BCC and HNSCC tumorigenesis have been shown to be associated with an aberrant canonical
Hh/GLI signaling pathway, mostly due to loss-of-function mutations in PTCH1, or gain-of-function
mutations in SMO [6,21,31]. Vismodegib, an approved drug for locally advanced or metastatic
BCC, antagonizes SMO receptor activation and reduces GLI expression by means of suppressor of
fused (SUFU) inhibitor [32]. First preclinical and clinical data have reported the feasibility of using
vismodegib in combination with radiation therapy in BCC patients [23–25]. Hence, we aimed to
investigate, whether inhibition of the Hh pathway using vismodegib might be feasible to overcome
BCC or HNSCC therapy resistance and to unravel underlying mechanisms.
Our findings indicate that BCC-1 cells and SCC-25 cells treated with vismodegib are less resistant
to irradiation and less viable when compared to untreated controls concomitant with a slight GLI1
and Survivin downregulation, cell cycle modulation and perturbed DNA repair. In more detail,
vismodegib-mediated Hh inhibition significantly decreased the number of viable BCC-1- and SCC-25
cells, as shown by a metabolic MTS assays (Figure 1). These observations are in line with data from Steg
and colleagues [33] and Wu et al. [34], reporting similar results after SMO inhibition with cyclopamine in
human pancreatic cancer cells, or with vismodegib in colon cancer cells, respectively. In the present study,
addition of irradiation only slightly decreased the cellular viability (Figure 3), indicating a non-synergistic
effect of combined modality treatment at early times. Again, these findings are in line with a recent
report by Gonnissen et al. showing no impact of radiation therapy on proliferation of prostate cancer cells
pretreated with 1 or 10 µM vismodegib [35]. Thus, one may assume that a therapeutic effect of vismodegib
treatment may not be associated with a short-term inhibition of viability/proliferation but may cover other
mechanisms of toxicity. Against this background, we investigated the effect of combined vismodegib
and radiation treatment on long-term clonogenic radiation survival performed in more physiologic 3D
cell culture approaches (Figure 5). The development of 3D cell culture models, including laminin-rich
extracellular matrix (lrECM) as for the first time applied in the present study, has shown that these assays
provide results with a higher similarity to in vivo data than those obtained from conventional 2D cell
cultures [36–38]. Responses of 3D grown cells to drug treatment or ionizing radiation have especially
revealed an increased therapy resistance that reflects the in vivo situation to a higher extent [36,39].
Putative underlying mechanisms include morphological changes, altered cell-cell and cell-extracellular
matrix contacts, activating cell adhesion molecules and different intracellular signaling pathways,
differential gene expression or epigenetic changes [36,38,40]. In these more physiological conditions, our
data revealed a concentration-dependent radiosensitization of both BCC-1 and SCC-25 cells. Sensitizer
enhancement-ratios of approximately 1.5 for the relatively low concentration of 5 µM vismodegib (Table 1)
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suggest that combination therapy impacts on clinically relevant clonogenic endpoints. Similar effects
using conventional 2D assays on cyclopamine-treated human HN11 and TU167 HNSCC [16] and Colo-357
and SW-1990 pancreatic adenocarcinoma cells further support this assumption [41].
On a molecular level, vismodegib treatment slightly decreased GLI1 mRNA and protein
expression in both cell lines, while we observed Survivin downregulation upon vismodegib treatment
only on the protein level most pronounced at a concentration of 40 µM (Figure 2 and Figure S1).
Indeed, a multitude of post-translational modifications, including phosphorylation, acetylation
and ubiquitination, have been reported to mediate Survivin′s stability and functions (reviewed in
Reference [42]) that may account for the role of this protein in vismodegib-mediated cytotoxicity.
Moreover, cell cycle analysis revealed a G1 arrest in BCC-1 cells and a G2 arrest in SCC-25
cells upon combined vismodegib and radiation treatment, but not after sole vismodegib application
(Figure 3). GLI translocation to the nucleus has been reported to promote cell cycle progression [43], and
inhibition of GLI by GANT61 was shown to induce a G1 arrest in 22Rv1—but not in PC3 and DU145
pancreatic cancer cells, concomitant with radiosensitization only in p53 wildtype 22Rv1 cells [35].
SCC-25 cells used in our experiments are heterozygous for a p53 mutation [44,45], while the p53 status
of BCC-1 is not known at present. Against this background, we performed WB analysis indicating
that SCC-25 do not display detectable levels of the p53 protein, while BCC-1 revealed a pronounced
detection of the protein (Figure 2D). This may indicate that p53 expression in BCC-1 may be sufficient
to modulate e.g., induction of a G1 arrest [46] upon vismodegib/irradiation treatment.
Our results showed that cell death was slightly (but significantly) induced upon Hh inhibition,
and irradiation as indicated by an elevated SubG1 fraction 24 h after irradiation and 48 h after
vismodegib application (Figure 3D). Cleavage of PARP or Caspase 3 as typical indicators for a canonical
apoptotic cell death induction was not evident in our models. This may indicate that alternative cell
death mechanisms could contribute to the observed radiosensitizing effect. Although not in the
focus of the present experimental setup, further analyses will focus on e.g., non-caspase dependent
necroptosis [47], after combined vismodegib/radiation treatment. These findings are in line with
data from Shi and colleagues, indicating a lack of PARP and Caspase 3 cleavage in malignant pleural
mesothelioma cells upon treatment with the SMO inhibitor HhAntag [10]. Notably, the group further
reported on a decreased mRNA and protein expression of Survivin and decreased clonogenic survival
similar to our results. Interestingly, Mazumdar et al. described effective induction of cell death
concomitant with PARP cleavage and Caspase 3 activity in human colon carcinoma cells upon GLI
inhibition with GANT61, while upstream inhibition of SMO with cyclopamine was far less effective [48].
Cyclopamine also failed to induce significant apoptosis in human pancreatic carcinoma cells [41].
By contrast, colorectal cancer cells exhibited an increased apoptotic fraction when treated with 50 µM
vismodegib [34], suggesting that a cell line-dependent Hh/GLI canonical and/or non-canonical
signaling is responsible for induction of apoptotic cell death.
Data on an impact of Hh/GLI signaling on DNA damage response pathways, including base
excision repair, nucleotide excision repair, non-homologous end joining (NHEJ), and homologous
recombination (reviewed in Reference [27]), and own findings, of a modulation of DNA double-strand
break repair by Survivin [26,28], prompted us to analyze DNA repair capacity in our cellular models.
Vismodegib and radiation treatment enhanced residual radiation-induced DNA damage as assayed by
γH2AX/53BP1 foci detection in both cell lines investigated (Figure 4) indicating that the cytotoxic effect
is, at least in part, mediated by a hampered DNA damage response. These findings are concomitant
with reports in colon adenocarcinoma showing an upregulation of γH2AX, activation of Ataxia
telangiectasia mutated (ATM)/checkpoint kinase 2 (Chk2) upon GLI inhibition with GANT61 [48,49].
In conclusion, in the present study we provide preclinical evidence that inhibition of the Hh
signaling pathway by vismodegib may increase therapeutic efficacy in both BCC and HNSCC if
combined with ionizing radiation. Our findings thus support further preclinical studies on the
complex underlying mechanisms and on extended clinical investigation of Hh pathway inhibition by
radiation therapy to explore the tolerability, and clinical efficacy of this combination in these entities.
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4. Materials and Methods
4.1. Cell Culture
A human basal cell carcinoma line BCC-1/KMC (BCC-1) was established by Chiang et al. [50]
and kindly provided by the National Taiwan University (Taipei, Taiwan). SCC-25 (ATCC® CRL1628™)
human HNSCC were purchased from the American Type Culture Collection (LGC Standards,
Wesel, Germany). The basaloid keratinocyte nature of these BCC-1 cells was verified by the presence of
keratin 14 mRNA, as measured by performing real-time RT-PCR [51]. The BCC-1 cells were maintained
in GibcoTM RPMI medium 1640 (Thermo Fisher Scientific, Darmstadt, Germany) with 10% fetal
bovine serum (FBS) superior (Merck, Darmstadt, Germany) and 100 units penicillin/mL/100 µg
Streptomycin/mL (P/S) (Sigma-Aldrich, Munich, Germany) at 37 ◦C in a humidified atmosphere with
5% CO2. The SCC-25 cells were maintained in Dulbecco’s Modified Eagle’s Medium nutrient mixture
F-12 Ham (Sigma-Aldrich), supplemented with 20% FBS and P/S at 37 ◦C in a humidified atmosphere
with 5% CO2.
4.2. Vismodegib Treatment and Irradiation Procedure
Cells were treated with 5 to 40 µM vismodegib (Hölzel Diagnostika, Cologne, Germany) or with
equivalent amounts of the solvent dimethyl sulfoxide (DMSO; AppliChem, Darmstadt, Germany) 24 h
before irradiation or for indicated time periods. Irradiation with single doses of 2, 4, 6 or 8 Gy was
performed using a linear accelerator (Elekta Synergy, Elekta, Crawley, UK) with 6 MV photon energy,
100 cm focus to isocentre distance and a dose rate of 6 Gy/min. To guarantee equal conditions control
cells were kept in equivalent surroundings in the irradiation control room.
4.3. Cell Proliferation (MTS) Assay
BCC-1 cells (2500 cells per well) and SCC-25 cells (4000 cells per well) were plated in 96-well
plates and cultured for 24 h before treatment with vismodegib. After 48 h of vismodegib treatment
without and in combination with irradiation (4 Gy after 24 h), a colorimetric cell proliferation assay
(CellTiter 96® Aqueous One Solution Cell Proliferation (MTS) Assay, Promega, Mannheim, Germany)
was carried out according to the manufacturer’s instructions. Absorbance at 490 nm (reference 570 nm)
was recorded with a 96-well microplate reader (Infinite M200 Pro, TECAN, Männedorf, Switzerland).
All experiments were carried out independently three to five times, each in quadruplicate.
4.4. Western Blot Analysis
According to the scheme shown in Figure 2A, cell lysis was accomplished with radio-
immunoprecipitation assay (RIPA) buffer at 24 or 48 h after vismodegib treatment. Total cell lysates
containing 40 µg of protein were prepared in sodium dodecyl sulfate (SDS) sample buffer, separated on
10% SDS polyacrylamide gels, and transferred to a nitrocellulose membrane (GE Healthcare, Munich,
Germany) for immunodetection with the following specific primary antibodies: Anti-GLI1 (2534, Cell
Signaling, Frankfurt, Germany), anti-Survivin (AF886, R&D Systems, Wiesbaden, Germany), anti p53
(DO-1; sc-126, Santa Cruz Biotechnology, Heidelberg, Germany), anti-PARP (9542) and anti-Caspase-3
(9662), both from Cell Signaling. For detection, blots were incubated with goat anti-rabbit (4050-05) or
goat anti-mouse (1030-05) horseradish peroxidase-linked antibodies (Biozol, Eching, Germany) and
finally visualized with chemiluminescence using Pierce ECL Western Blotting Substrate (Thermo Fisher
Scientific) and the Odyssey Fc imaging system (LI-COR Biotechnology, Bad Homburg, Germany).
To confirm equal loading of protein amounts, a β-actin antibody was used (A5441, Sigma-Aldrich).
Densitometric analysis for GLI1 and Survivin protein content was performed with the Image Studio
Lite version 5.0 software (LI-COR Biotechnology), normalized to β-actin expression and presented
relative to DMSO-treated controls.
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4.5. RNA Preparation and Quantitative Real-Time RT-PCR
Measurement of GLI1 or Survivin mRNA expression of BCC-1 and SCC-25 cells after 24
and 48 h treatment with vismodegib was accomplished by isolation of RNA using TRI Reagent®
(Sigma-Aldrich) according to the manufacturer’s recommendations. The time schedule for cell
treatment and lysis is displayed in Figure 2A. Subsequently, RNA was reverse-transcribed with
Omniscript® Reverse Transcription Kit (Qiagen, Hilden, Germany) and quantitative real-time RT-PCR
was performed using the StepOnePlus Real-Time PCR System (Thermo Fisher Scientific) and SYBR®
Green JumpStartTM Taq ReadyMixTM (Sigma-Aldrich). PCR assays were performed in triplicate
according to the manufacturer’s instruction with the following PCR conditions/thermo-profile:
2 min at 94 ◦C, followed by 40 cycles of 15 s at 94 ◦C and 1 min at 54 ◦C (ribosomal protein L37A
(RPL37A) and BIRC5) or 60 ◦C (GLI1). Relative gene expression was calculated using the 2−∆∆Ct
method with the housekeeping gene RPL37A as reference and is displayed as mean values relative to
DMSO-treated non-irradiated controls + standard deviation (SD). The sequences of the primer pairs
were as follows: Survivin (gene name: BIRC5): BIRC5-fw 5′-CCCAGTGTTTCTTCTGCTTCAAG-3′,
BIRC5-rev 5′-CAACCGGACGAATGCTTTTT-3′; (design: R. Wirtz, Stratifyer Molecular Pathology,
Cologne, Germany; manufacturer: Eurofins Genomics, Ebersberg, Germany); GLI1: GLI1-fw:
5′-CTGTCCCATCCCGAACTCTC-3′, GLI1-rev: 5′-CCACCCATATCTCCCCTTCA-3′ (Integrated DNA
Technologies (IDT), Leuven, Belgium); RPL37A: RPL37A-fw 5′-TGTGGTTCCTGCATGAAGACA-3′,
RPL37A-rev 5′-GTGACAGCGGAAGTGGTATTGTAC-3′ [52] (manufacturer: Eurofins Genomics).
For each data point two independent experiments were acquired and performed in duplicate.
4.6. Cell Cycle and Apoptosis Analysis
Analysis of cell cycle distribution and SubG1 population of BCC-1 and SCC-25 cells was performed
with a CytoFlex flow cytometer (Beckman Coulter, Krefeld, Germany). Briefly, cells were plated in
6-well plates and treated with indicated amounts of vismodegib as described before. At 24 h after
inhibitor treatment, the cells were irradiated (4 Gy, single dose; Figure 3A). A subsequent 24 h later,
cells were trypsinized, washed with phosphate-buffered saline (PBS) (Thermo Fisher Scientific) and
fixed with 80% ethanol at −20 ◦C for 10 min. After centrifugation (200× g for 5 min), cell pellets were
resuspended in PBS containing 40 µg/mL propidium iodide (Sigma-Aldrich) and 40 µg/mL RNase A
(Qiagen) and incubated for 30 min at 37 ◦C before measurement. Finally, cells were gated to exclude
cell debris and analyzed by flow cytometry in linear mode by using the CytExpert Software (Beckman
Coulter). Mean values and standard deviations were calculated by considering four independent
experiments, each performed in duplicate.
4.7. Immunofluorescence Staining and Quantification of γH2AX/53BP1 Foci Formation
Analysis of residual DNA damage 24 h after irradiation was performed by quantification of
γH2AX/53BP1-positive nuclear foci, a surrogate marker for DNA DSB, as described before [53].
Briefly, cells were plated on microscope cover slips and treated 24 h later with DMSO or with 10 or 40 µM
vismodegib in 12-well plates (Greiner Bio-One, Frickenhausen, Germany) for 24 h. Cells were irradiated
(0, 4 Gy) and 24 h thereafter fixed and permeabilized using 3.7% paraformaldehyde/0.25% Triton
X-100 (AppliChem) diluted in PBS for 10 min. Blocking was performed in 5% bovine serum albumin
(AppliChem) for 1 h and γH2AX/53BP1-positive foci were visualized with anti-γH2AX (clone JBW301,
05-636, Merck), anti-53BP1 (100-304, Novus Biologicals, Wiesbaden Nordenstadt, Germany) primary
and fluorescent-dye conjugated secondary antibodies (Alexa Fluor 594 goat anti-mouse, Alexa Fluor
488 goat anti-rabbit, Thermo Fisher Scientific). Nuclei were stained with 4′,6-diamidino-2-phenylindole
(DAPI) solution (AppliChem) and after mounting of cover slips with Vectashield mounting medium
(Alexis, Grünberg, Germany), γH2AX/53BP1-positive nuclear foci were microscopically counted with
an AxioImager Z1 microscope (Carl Zeiss, Jena, Germany). For each condition 50 nuclei were evaluated
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by considering three independent experiments performed in duplicate. Fluorescence images were
acquired with an AxioImager Z1 microscope and AxioVision 4.6 software (Carl Zeiss).
4.8. 3D Colony Formation Assay
Evaluation of 3D clonogenic survival was performed as previously described [29]. Briefly, BCC-1
or SCC-25 cells were diluted in 0.5 mg/mL laminin-rich extracellular matrix (lrECM; BME Growth
Factor Reduced PathClear) from Biozol at 500 or 400 cells per well. Vismodegib was applied 24 h
thereafter at concentrations ranging from 5 to 40 µM. Controls were treated with equivalent amounts
of DMSO solvent. 24 h after treatment, cells were irradiated (0–8 Gy, single doses) and 3D colonies
>50 cells were counted microscopically 7 days after plating (Axio Vert.A1, 2.5-x objective, Carl Zeiss).
Images of typical colony formation were acquired by phase contrast microscopy using an inverted
microscope (Nikon TS100, Nikon, Düsseldorf, Germany). Plating efficiencies were measured as follows:
Numbers of colonies formed after DMSO or vismodegib treatment /numbers of cells plated. Surviving
fractions (SF) were calculated according to: Numbers of colonies formed / (numbers of cells plated
(irradiated) × plating efficiency (non-irradiated, DMSO or vismodegib treated). For each point on
the survival curves the mean surviving fraction from three independent experiments performed
in triplicate repeats was calculated. Survival variables α, β were fitted according to the linear
quadratic equation SF = exp [−α × D – β × D2] with D = dose (EXCEL software, Microsoft, version
Office Professional Plus 2010, Redmond, WA, USA). A summary of radiation response variables and
radiation-induced sensitizer enhancement ratios at 50% and 10% cell survival can be found in Table 1.
4.9. Statistical Analysis
Results are expressed as means ± SD calculated with GraphPad Prism (GraphPad Software, Inc.,
version 5, La Jolla, CA, USA) or EXCEL software. The unpaired two-tailed t-test was applied for
statistical analysis (EXCEL software), while a p-value < 0.05 was considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/9/
2485/s1.
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Abbreviations
3D Three-dimensional
53BP1 p53-binding protein 1
BCC Basal cell carcinoma
DSB Double-strand break
GLI Glioma-associated oncogene homologue 1
Hh Hedgehog
HNSCC Head and neck squamous cell carcinoma
IAP Inhibitor of apoptosis protein
PARP Poly ((adenosine diphosphate)ADP-ribose) polymerase
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PTCH1 Patched homologue 1
SCC Squamous cell carcinoma
SMO Smoothened
SUFU Suppressor of fused
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